{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:35:13Z","timestamp":1783964113614,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40801-025-00493-y","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T21:28:59Z","timestamp":1747430939000},"page":"295-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review"],"prefix":"10.1007","volume":"12","author":[{"given":"Austin","family":"Luong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Poei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Angell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-366X","authenticated-orcid":false,"given":"Jacob","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"6","key":"493_CR1","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1067\/msy.2001.118266","volume":"130","author":"B McIver","year":"2001","unstructured":"McIver B, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130(6):1028\u201334.","journal-title":"Surgery"},{"issue":"11","key":"493_CR2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge RC, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104\u201339.","journal-title":"Thyroid"},{"issue":"6","key":"493_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486\u201397.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"493_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol. 2020;6(9):1397\u2013404.","journal-title":"JAMA Oncol"},{"issue":"12","key":"493_CR5","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","volume":"102","author":"N Prasongsook","year":"2017","unstructured":"Prasongsook N, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2017;102(12):4506\u201314.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"493_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjoto.2017.02.005","volume":"38","author":"S Hu","year":"2017","unstructured":"Hu S, et al. The role of surgery in anaplastic thyroid cancer: a systematic review. Am J Otolaryngol. 2017;38(3):337\u201350.","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"493_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1748-717X-9-90","volume":"9","author":"AK Dumke","year":"2014","unstructured":"Dumke AK, Pelz T, Vordermark D. Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol. 2014;9(1):90.","journal-title":"Radiat Oncol"},{"issue":"12","key":"493_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamaoto.2015.2332","volume":"141","author":"Y Nachalon","year":"2015","unstructured":"Nachalon Y, et al. Aggressive palliation and survival in anaplastic thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2015;141(12):1128\u201332.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"493_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, et al. 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337\u201386.","journal-title":"Thyroid"},{"issue":"1","key":"493_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/thy.2009.0115","volume":"20","author":"T Higashiyama","year":"2010","unstructured":"Higashiyama T, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010;20(1):7\u201314.","journal-title":"Thyroid"},{"issue":"7","key":"493_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1089\/thy.2000.10.587","volume":"10","author":"KB Ain","year":"2000","unstructured":"Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid. 2000;10(7):587\u201394.","journal-title":"Thyroid"},{"issue":"3","key":"493_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa I, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052\u201366.","journal-title":"J Clin Invest"},{"issue":"6","key":"493_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573\u2013604.","journal-title":"Endocr Rev"},{"issue":"4","key":"493_CR14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406\u201315.","journal-title":"Ann Oncol"},{"issue":"6","key":"493_CR15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar AV, et al. Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab. 2017;102(6):1943\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"493_CR16","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620\u20137.","journal-title":"J Clin Oncol"},{"key":"493_CR17","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2022.07.1726","volume":"33","author":"C Dierks","year":"2022","unstructured":"Dierks C, et al. 1646MO Phase II ATLEP trial: final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol. 2022;33:S1295.","journal-title":"Ann Oncol"},{"issue":"8","key":"493_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/cancers11081188","volume":"11","author":"J Sim\u00f5es-Pereira","year":"2019","unstructured":"Sim\u00f5es-Pereira J, et al. Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options. Cancers (Basel). 2019;11(8):1188.","journal-title":"Cancers (Basel)"},{"key":"493_CR19","doi-asserted-by":"publisher","first-page":"8218949","DOI":"10.1155\/2019\/8218949","volume":"2019","author":"KL Corrigan","year":"2019","unstructured":"Corrigan KL, et al. Treatment outcomes in anaplastic thyroid cancer. J Thyroid Res. 2019;2019:8218949.","journal-title":"J Thyroid Res"},{"issue":"2","key":"493_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cncr.32548","volume":"126","author":"D Fan","year":"2020","unstructured":"Fan D, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer. 2020;126(2):444\u201352.","journal-title":"Cancer"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00493-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00493-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:08:08Z","timestamp":1750129688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00493-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00493-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"27 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jacob Thomas has received consulting fees from Kura Oncology, Inc. and Coherus BioSciences, Inc. The remaining authors have no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. We consulted extensively with the IRB of the University of Southern California, who determined that our study did not need ethical approval. An IRB official waiver of ethical approval was granted from the IRB of the University of Southern California.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AL and JT conceptualized this article. Data curation and formal analysis were performed by AL, ML, QN, and JT. All authors contributed to the investigation, writing, reviewing, and editing of the manuscript. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}